Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

597 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correspondence to 'Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases'.
Schulze-Koops H, Skapenko A, Krause A, Krueger K, Lorenz HM, Sewerin P, Specker C, Wagner UG, Voormann A, Mueller-Ladner U, Voll RE. Schulze-Koops H, et al. Among authors: krueger k. Ann Rheum Dis. 2023 Jan;82(1):e1. doi: 10.1136/annrheumdis-2020-218997. Epub 2020 Oct 30. Ann Rheum Dis. 2023. PMID: 33127664 No abstract available.
Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment.
Rech J, Hueber AJ, Finzel S, Englbrecht M, Haschka J, Manger B, Kleyer A, Reiser M, Cobra JF, Figueiredo C, Tony HP, Kleinert S, Wendler J, Schuch F, Ronneberger M, Feuchtenberger M, Fleck M, Manger K, Ochs W, Schmitt-Haendle M, Lorenz HM, Nuesslein H, Alten R, Henes J, Krueger K, Schett G. Rech J, et al. Among authors: krueger k. Ann Rheum Dis. 2016 Sep;75(9):1637-44. doi: 10.1136/annrheumdis-2015-207900. Epub 2015 Oct 19. Ann Rheum Dis. 2016. PMID: 26483255 Free PMC article. Clinical Trial.
Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs.
Figueiredo CP, Bang H, Cobra JF, Englbrecht M, Hueber AJ, Haschka J, Manger B, Kleyer A, Reiser M, Finzel S, Tony HP, Kleinert S, Wendler J, Schuch F, Ronneberger M, Feuchtenberger M, Fleck M, Manger K, Ochs W, Schmitt-Haendle M, Lorenz HM, Nuesslein H, Alten R, Henes J, Krueger K, Rech J, Schett G. Figueiredo CP, et al. Among authors: krueger k. Ann Rheum Dis. 2017 Feb;76(2):399-407. doi: 10.1136/annrheumdis-2016-209297. Epub 2016 Jun 20. Ann Rheum Dis. 2017. PMID: 27323772
Preliminary recommendations of the German Society of Rheumatology (DGRh eV) for the management of patients with inflammatory rheumatic diseases during the SARS-CoV-2/COVID-19 pandemic.
Schulze-Koops H, Specker C, Iking-Konert C, Holle J, Moosig F, Krueger K. Schulze-Koops H, et al. Among authors: krueger k. Ann Rheum Dis. 2020 Jun;79(6):840-842. doi: 10.1136/annrheumdis-2020-217628. Epub 2020 Apr 28. Ann Rheum Dis. 2020. PMID: 32345619 No abstract available.
Treatment of patients with inflammatory rheumatic diseases with rituximab should be carefully considered during the SARS-CoV-2/COVID-19 pandemic. Response to: 'Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koops et al' by Benucci et al.
Schulze-Koops H, Krueger K, Vallbracht IV, Hasseli R, Skapenko A. Schulze-Koops H, et al. Among authors: krueger k. Ann Rheum Dis. 2022 Aug 11;81(9):e185. doi: 10.1136/annrheumdis-2020-218686. Ann Rheum Dis. 2022. PMID: 32753421 No abstract available.
597 results